37% Insurance Growth Masks Consolidated Loss; Demerger Blocked

₹2,229 Cr insurance revenue (+28% Ind AS basis, 37% GWP validated). Market share 6.7% overall, 24% SAHI segment confirmed.

PBT ₹10 Cr (+53% YoY confirmed). Revenue ₹99.5 Cr (+7% YoY), but QoQ flat per analyst notes—modest growth not 'strong rebound'.

AUM stagnant ₹247 Cr (flat YoY), loss ₹5 Cr Q1 (vs prior 12-18 month profitability target). Capital earmarked but deployment timeline still vague.

SME book only ₹53 Cr after 6+ months since embargo lifted. ₹600 Cr cash idle. Timeline unproven and non-binding.

Ratio 102.6% (down 30 bps), tracking on plan but still elevated vs peers. Achievement valid but pace slow.

Q1 FY28 target removed. RBI gave no reasoning. Management claims re-engagement, but timeline now indefinite. Major strategic U-turn for value unlock thesis.

Prior: 12-18 months to breakeven. Q1 FY27: still -₹5 Cr loss, AUM flat ₹247 Cr. New timeline: unspecified. Target window missed.

Prior: unspecified readiness. Now: 'next 3-4 months' (from Aug 2026 = Nov-Dec launch). SME book only ₹53 Cr, ₹600 Cr idle. Non-binding forecast.

Q1 +7% YoY, but QoQ flat. Management calls it 'temporary blip' during platform rebuild, but sequential trend weak despite profitability gains.

Letter is brief with no reasoning. Engaging with regulator. No alternatives being pursued currently. Timeline TBD post re-engagement.

Corporate wellness upfront claims explain ratio. Started 103%, landed 101% last year; targeting 100% in 2 years. Fresh business growing fastest; consumer count growing in tier 2-3.

Cannot comment on full year. Market has been supportive. We intend to beat market.

Will reduce to 3.7x with capital infusion this year. Promoters have earmarked pref capital.

₹1.5-2K Cr capital (including ₹250 Cr commitment) targeting ₹10-15K Cr AUM. Teams working AOPs, will come back.

Fair assessment as of now. Will get clarity post re-engagement with regulator.

Solvency met with ₹200 Cr sub-debt (Aug 2026). Plan to maintain 1.7x. REL committed to funding. Warrant conversions provide buffer.

Pool is ₹350-400 Cr, dwindling book. Litigation/repossession delays noted. Legacy NPA recovery will decline quarterly. Cannot give exact numbers.

Lending was under embargo 6-7 years. Rebuilding tech, soft-launching product. Cash to be deployed next 3-4 months. Will see profile change significantly.

No. Engaging with regulator only. Not under consideration right now.

Vague market-dependent language. Prior 18-24% GWP beaten at 37%, but no new ceiling set. Implies expectations-management mode.

Multi-year horizon, conditional on NBFC/housing product launches. Unproven execution. Capital earmarked but deployment unvalidated.

Currently 102.6% (-30 bps YoY). On trajectory but elevated vs peers. Dependent on corporate wellness segment normalization and loss ratio discipline.

Q1 result ₹5 Cr loss. Timeline window expired without inflection. No new profitability ETA disclosed. Credibility eroded.

Capital earmarked by promoters (pref shares, rights issues). Schedule vague ('next few years'). Deployment unproven; execution risk remains.

RBI rejected demerger application without providing specific reasoning. Value unlocking strategy delayed indefinitely. No alternative path disclosed or timeline provided. Major setback for investors betting on conglomerate discount reduction.

Guided to reach profitability within 12-18 months from prior call; Q1 FY27 still shows ₹5 Cr loss. AUM stagnant at ₹247 Cr YoY, flat growth. Credibility eroded; new profitability timeline not provided.

Religare Finvest promised to launch new products and scale business within 3-4 months (from Aug 2026 = Q2-Q3 FY27). Current SME book only ₹53 Cr after 6+ months post-embargo lifting. ₹600 Cr cash sitting idle; deployment unproven and non-binding.

Care's combined ratio at 102.6% is meaningfully higher than several peers who have reported Q1 FY27 results. Raises question on competitive pricing power and loss-making segments. Corporate wellness upfront claim accounting adds complexity.

Despite Care ₹163 Cr PBT, consolidated net loss of ₹47 Cr (vs +₹5.73 Cr YoY profit). YoY swing -₹674.9% (profit to loss). FS segment (broking ₹10 Cr, RFL ₹15 Cr, housing -₹5 Cr) unable to support group. Profitability trajectory negative.